Skip to main content
Barry A. Kriegsman on Muck Rack

Barry A. Kriegsman

As seen in: JAMA (The Journal of the American Medical Association), The Journal of Immunology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Barry A.

Contact Barry A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors

|
By Barry A. Kriegsman, Jason Newman, Sara B. Hobday, Robert M. Brody
| JAMA (The Journal of the American Medical Association) Verified
Key Points Question What are response rates and survival outcomes among patients with mucosal head and neck squamous cell carcinoma (HNSCC) in the general population who are treated with checkpoint inhibitors? Findings In this cohort study of 212 patients with HNSCC, including 66 with an Eastern Cooperative Oncology Group performance status of 2 or greater, the overall response rate was 30.1% and estimated 1-year overall survival and progression-free survival were 51.8% and 9.4%, respectively.
Open in Who Shared Issue with article?

Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression

|
By Barry A. Kriegsman, Pranitha Vangala, Benjamin Chen, Paul Meraner
| The Journal of Immunology Verified
Barry A. Kriegsman, Pranitha Vangala, Benjamin J. Chen, Paul Meraner, Abraham L. Brass, Manuel Garber and Kenneth L. Rock J Immunol October 1, 2019, 203 (7) 1999-2010; DOI: https://doi.org/10.4049/jimmunol.1900475 Key Points Many primary human cancers frequently downregulate the transcription factor IRF2. IRF2 loss causes an immune evasion phenotype of low MHC-I and high PD-L1. The MHC-I defect in IRF2-low cells can be restored upon IFN stimulation.
Open in Who Shared Issue with article?

Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression

|
By Benjamin Chen, Paul Meraner, Barry A. Kriegsman, Pranitha Vangala
| The Journal of Immunology Verified
Barry A. Kriegsman, Pranitha Vangala, Benjamin J. Chen, Paul Meraner, Abraham L. Brass, Manuel Garber and Kenneth L. Rock J Immunol August 30, 2019, ji1900475; DOI: https://doi.org/10.4049/jimmunol.1900475 Key Points Many primary human cancers frequently downregulate the transcription factor IRF2. IRF2 loss causes an immune evasion phenotype of low MHC-I and high PD-L1. The MHC-I defect in IRF2-low cells can be restored upon IFN stimulation.
Open in Who Shared Issue with article?
See all 3 articles